Your browser doesn't support javascript.
loading
Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
Gunaratne, Preethi H; Pan, Yinghong; Rao, Abhi K; Lin, Chunru; Hernandez-Herrera, Anadulce; Liang, Ke; Rait, Antonina S; Venkatanarayan, Avinashnarayan; Benham, Ashley L; Rubab, Farwah; Kim, Sang Soo; Rajapakshe, Kimal; Chan, Clara K; Mangala, Lingegowda S; Lopez-Berestein, Gabriel; Sood, Anil K; Rowat, Amy C; Coarfa, Cristian; Pirollo, Kathleen F; Flores, Elsa R; Chang, Esther H.
Afiliação
  • Gunaratne PH; Department of Biochemistry and Biology, University of Houston, Houston, Texas.
  • Pan Y; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, Texas.
  • Rao AK; Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas.
  • Lin C; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
  • Hernandez-Herrera A; Department of Biochemistry and Biology, University of Houston, Houston, Texas.
  • Liang K; UPMC Genome Center, Pittsburgh, Pennsylvania.
  • Rait AS; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia.
  • Venkatanarayan A; Department of Molecular and Cellular Oncology, Division of Basic Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Benham AL; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
  • Rubab F; Department of Molecular and Cellular Oncology, Division of Basic Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kim SS; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia.
  • Rajapakshe K; Department of Molecular and Cellular Oncology, Division of Basic Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chan CK; Genentech, Inc., South San Francisco, California.
  • Mangala LS; Department of Biochemistry and Biology, University of Houston, Houston, Texas.
  • Lopez-Berestein G; 10X Genomics Inc., Pleasanton, California.
  • Sood AK; SynerGene Therapeutics, Inc., Potomac, Maryland.
  • Rowat AC; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia.
  • Coarfa C; SynerGene Therapeutics, Inc., Potomac, Maryland.
  • Pirollo KF; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, Texas.
  • Flores ER; Department of Integrative Biology and Physiology, University of California, Los Angeles, California.
  • Chang EH; Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 125(14): 2409-2422, 2019 07 15.
Article em En | MEDLINE | ID: mdl-31012964
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Fatores de Transcrição / Ativação Transcricional / Proteína Supressora de Tumor p53 / Mutação de Sentido Incorreto / Proteínas Supressoras de Tumor / MicroRNAs Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Fatores de Transcrição / Ativação Transcricional / Proteína Supressora de Tumor p53 / Mutação de Sentido Incorreto / Proteínas Supressoras de Tumor / MicroRNAs Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Ano de publicação: 2019 Tipo de documento: Article